Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association’s 2026 Scientific Sessions
Glucotrack will present its fully implantable continuous blood glucose monitoring (CBGM) technology at the American Diabetes Association’s 2026 Scientific Sessions in New Orleans. The presentation highlights recent peer-reviewed studies demonstrating year-long enzyme stability and sustained accuracy with a 6.8% MARD over 240 days in an ovine model. The company also confirmed it has submitted an Investigational Device Exemption (IDE) application to the FDA, a prerequisite for initiating a U.S.
Key figures
- Mard
- 6.8%
- Study duration days
- 240
- Sensor longevity years
- 3
- Glucose tolerance tests
- 79
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.